A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Recruiting

• Conditions: Non-small Cell Lung Cancer Stage IIIA

• Registration Number: NCT05732974
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Detailed Description

This study will use data from an already available cohort of patients enrolled in the Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a new concurrent cohort as validation set.

Study Timeline

• Study First Submitted: 2022-11-14
• Study First Submitted QC: 2023-02-08
• Study First Posted: 2023-02-17
• Study Start: 2023-03-30
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-18
• Last Update Posted: 2023-09-21
• Primary Completion: 2025-11-30
• Study Completion: 2026-10-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patient with an early stage of non small cell lung cancer
• Indication of surgical resection
• Patient able to understand and give his consent
• Patient affiliated to the health insurance

Exclusion Criteria

• Patient with another cancer in the last 5 years
• Patient with an allergy to the contrast medium
• Patient under legal protection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Algorithm for disease free survival	18 months	Analysis on a training cohort of resected early-stage non small cell lung cancer

Trial Locations

Locations (1)

Julien MAZIERES; 🇫🇷 Toulouse, France